Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iMMagine-3: Anitocabtagene Autoleucel vs SOCT in RRMM
NCT06413498Phase 3Active, not recruiting
- Sponsor
- Kite Pharma
- Start
- Aug 2024
- Primary completion
- Jul 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Anitocabtagene Autoleucel with Standard of Care Therapy (SOCT) (2 arms). Primary endpoints: Progression-Free Survival up to 4 years and Minimal Residual Disease Complete Response Rate up to 9 months. Started Aug 2024; status: active, not recruiting.
02
Drugs
anitocabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06413498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06413498.